证券代码：300622 证券简称：博士眼镜 公告编号：2024-069 博士眼镜连锁股份有限公司 2024 年第二次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会没有否决或变更议案的情况发生； 2、本次股东大会不涉及变更前次股东大会决议。 一、会议召开和出席情况 （一）会议召开情况 7、本次股东大会的召集、召开符合《中华人民共和国公司法》《上市公司 股东大会规则》《深圳证券交易所创业板股票上市规则》等法律法规、规范性文 件及《博士眼镜连锁股份有限公司章程》的相关规定。 （二）会议出席情况 1、博士眼镜连锁股份有限公司（以下简称"公司"）于 2024 年 8 月 27 日 召开第五届董事会第五次会议审议通过了《关于召开 2024 年第二次临时股东大 会的议案》，通知内容详见 2024 年 8 月 29 日公司披露于巨潮资讯网 （www.cninfo.com.cn）的《博士眼镜连锁股份有限公司关于召开公司 2024 年第 二次临时股东大会的通知》（公告编号：2024-067）。 2、会议召开时间： （1）现场会议 ...

债权人如果提出要求公司清偿债务的，应根据《中华人民共和国公司法》等相 关法律法规的规定，向公司提出书面请求，并随附相关证明文件。 特此公告。 1 博士眼镜连锁股份有限公司 董事会 证券代码：300622 证券简称：博士眼镜 公告编号：2024-070 博士眼镜连锁股份有限公司 关于回购注销部分限制性股票的减资公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 博士眼镜连锁股份有限公司（以下简称"公司"）于 2024 年 7 月 5 日召开第五 届董事会第四次会议、2024 年 9 月 20 日召开 2024 年第二次临时股东大会，审议 通过了《关于调整 2021 年限制性股票与股票期权激励计划限制性股票回购价格及 回购注销部分限制性股票的议案》。鉴于限制性股票 2 名激励对象个人层面绩效考 核结果仅达到部分解除限售条件，公司回购注销上述 2 名激励对象已获授但尚未解 除限售的7,200 股限制性股票。回购注销完成后，公司注册资本相应减少7,200 元， 总股本相应减少 7,200 股。具体内容详见 2024 年 7 月 6 日公司披露于巨潮资讯网 （www. ...

北京│上海│深圳│杭州│广州│昆明│天津│成都│宁波│福州│西安│南京│南宁│济南│重庆│苏州│长沙│太原│武汉│贵阳│乌鲁木齐│郑州│石家庄│合肥│海南│青岛│拉孜 │香港│巴黎│马德里│斯德哥尔摩│纽约 BEIJING │SHANGHAI │SHENZHEN│HANGZHOU │GUANGZHOU│KUNMING │TIANJIN│CHENGDU│NINGBO │FUZHOU │XI'AN │NANJING│NANNING│JINAN│CHONGQING│SUZHOU│CHANGSHA│ 国浩律师（深圳）事务所 关于博士眼镜连锁股份有限公司 TAIYUAN│ WUHAN│GUIYANG│URUMQI│ZHENGZHOU│SHIJIAZHUANG│HEFEI│HAINAN│QINGDAO│LAZI│ HONG KONG│ PARIS│MADRID│STOCKHOLM│NEW YORK 博士眼镜 2024 年第二次临时股东大会法律意见书 实进行了核查和验证，现根据本所律师对事实的了解及对法律的理解，出具法律 意见如下： GLG/SZ/A2426/FY/2024-947 致：博士眼镜连锁股份有限公司 国浩律师（ ...

政旦志远（深圳）会计师事务所（特殊普通合伙）成立日期为 2005 年 1 月 12 日，注册地址为深圳市福田区莲花街道福新社区鹏程一路 9 号广电金融中心 14F，执行事务合伙人为张建栋。更名后，原"深圳大华国际会计师事务所（特 殊普通合伙）"的各项业务、权利和义务由"政旦志远（深圳）会计师事务所（特 殊普通合伙）"承继。 因此，公司 2024 年度财务审计机构名称变更为"政旦志远（深圳）会计师 事务所（特殊普通合伙）"。本次会计师事务所变更事项仅为名称变更，不涉及 主体资格变更，不属于更换或重新聘任会计师事务所事项。 特此公告。 证券代码：300622 证券简称：博士眼镜 公告编号：2024-068 博士眼镜连锁股份有限公司 关于会计师事务所更名的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 博士眼镜连锁股份有限公司（以下简称"公司"）于 2024 年 5 月 22 日召开 了 2023 年度股东大会，审议通过了《关于拟聘任会计师事务所的议案》，同意 聘任深圳大华国际会计师事务所（特殊普通合伙）为公司 2024 年度财务审计机 构。 公司于近日收到深 ...

Investment Rating - The report maintains a "Buy" rating for the company, with projected net profits of 140 million, 170 million, and 200 million yuan for 2024-2026, corresponding to P/E ratios of 34.3X, 28.5X, and 24.8X respectively [1] Core Views - The AR glasses market is experiencing rapid growth, with global and Chinese AR device shipments reaching 510,000 and 200,000 units in 2023, up 37.8% and 53.9% YoY respectively [1] - The company has a significant channel advantage, with a nationwide network of stores and partnerships with major AR players like Huawei, Rokid, and Thunderbird [1] - Customization capabilities in lenses are becoming a key competitive factor, with strong demand for digital, photochromic, and youth myopia control lenses [1] Industry Overview - The AR glasses market is highly concentrated, with the top 5 players accounting for 89.9% of the Chinese market in 2023 [1] - XREAL leads the global consumer AR market with an 81% share in H1 2022 [1] - The global AR device market is expected to reach 5 million units by 2027, with a CAGR of 77.0% from 2023-2027 [14] Company Strategy - The company is strengthening its position in the smart glasses sector through strategic investments and joint ventures, such as the planned collaboration with Thunderbird to develop a domestic version of Meta Ray-Ban [1] - It has established partnerships with multiple AR players, providing online prescription services and offline channel networks [1] - The company is expanding its retail network, with 515 stores nationwide as of 2023, including 495 directly operated stores [28] Financial Performance - Revenue is projected to grow from 1.176 billion yuan in 2023 to 1.771 billion yuan in 2026, with a CAGR of 14.6% [2] - Net profit attributable to shareholders is expected to increase from 128 million yuan in 2023 to 195 million yuan in 2026 [2] - The company's ROE is forecast to rise from 16.2% in 2023 to 18.5% in 2026 [2] Market Opportunities - The myopia control lens market in China is expected to exceed 30 million units by 2030, with a penetration rate of 30% and a market size of over 60 billion yuan [34] - The presbyopia lens market is driven by aging population and consumption upgrade trends, with annual demand of approximately 40 million pairs in China [36] - Emerging applications such as photochromic, night vision, and blue light blocking lenses present additional growth opportunities [42]

Investment Rating - The report maintains a "Buy" rating for the company, with projected net profits of 140 million, 170 million, and 200 million yuan for 2024-2026, corresponding to P/E ratios of 34.3X, 28.5X, and 24.8X respectively [1] Core Views - The AR glasses market is experiencing rapid growth, with global and Chinese AR device shipments reaching 510,000 and 200,000 units in 2023, up 37.8% and 53.9% YoY respectively [1] - The company has a significant channel advantage, with a nationwide network of stores and partnerships with major AR players like Huawei, Rokid, and Thunderbird [1] - Customization capabilities in lenses are becoming a key differentiator, with strong demand for digital, photochromic, and youth myopia control lenses [1] Market and Industry Analysis - The global AR device market is highly concentrated, with the top 5 players accounting for 89.9% of the Chinese market in 2023 and 55.7% globally in 2022 [1] - XREAL leads the global consumer AR market with an 81% share in H1 2022, while Thunderbird Innovation dominates the Chinese market with a 39.1% share in 2023 [1][17] - The AR industry is transitioning from B2B to B2C, with consumer sales accounting for 78.4% of the market in 2023 [1][14] Company Strategy and Positioning - The company is strengthening its position in the smart glasses sector through strategic investments and joint ventures, including a partnership with Thunderbird to develop a domestic version of Meta Ray-Ban [1] - It has established a comprehensive retail network across 23 provinces, leveraging partnerships with malls, supermarkets, and hospitals to enhance its channel capabilities [1] - The company is focusing on the integration of online and offline services, with a strong presence in both physical stores and e-commerce platforms [1] Financial Performance and Projections - Revenue is expected to grow from 1.176 billion yuan in 2023 to 1.771 billion yuan in 2026, with a CAGR of 14.6% [2] - Net profit attributable to shareholders is projected to increase from 128 million yuan in 2023 to 195 million yuan in 2026, with a CAGR of 15.1% [2] - The company's ROE is forecasted to rise from 16.2% in 2023 to 18.5% in 2026, indicating improving profitability [2] Product and Technology Trends - The AR glasses market is shifting towards lighter, more consumer-friendly designs, with magnetic/insertable myopia lenses becoming the mainstream [24] - Pre-installed prescription lenses are emerging as a key area of innovation, with companies like Apple and Meta investing heavily in this technology [24] - The company is actively participating in the development of advanced AR technologies, including partnerships for the production of customized lenses [24] Growth Opportunities - The myopia control market presents significant growth potential, with the penetration rate of defocus lenses expected to increase from 3.5% in 2021 to 30% by 2030 [33] - The aging population and rising consumer demand for premium products are driving growth in the presbyopia lens market, which currently accounts for only 1.5% of the total eyewear market [36] - Emerging applications such as photochromic, night vision, and anti-blue light lenses are creating new opportunities for companies with strong customization capabilities [42]

Investment Rating - The report maintains a "Buy" rating for the company [3] Core Views - The company reported stable operations with a breakthrough in smart glasses, achieving revenue of 601 million yuan in H1 2024, a year-on-year increase of 0.3%, while net profit attributable to shareholders was 52 million yuan, a decrease of 21.3% [1] - The growth rate of optical glasses and fitting services has slowed, but the company is steadily expanding its direct and franchise stores, with a total of 501 direct stores and 29 franchise stores as of the end of Q2 2024 [1] - The company is enhancing its digital retail system and steadily advancing its franchise model, with a significant increase in the sales proportion of functional lenses [1] - The company is exploring the smart glasses sector, establishing stable partnerships with leading brands and planning to develop new products [1] Financial Summary - For H1 2024, the company achieved revenues of 385 million yuan from optical glasses, 107 million yuan from fitting services, and 80 million yuan from contact lenses, with respective year-on-year growth rates of -2.4%, +7.8%, and +3.6% [1] - The company expects net profits for 2024, 2025, and 2026 to be 140 million yuan, 170 million yuan, and 195 million yuan, respectively, with corresponding P/E ratios of 34X, 28X, and 25X [1][2] - The company’s revenue is projected to grow from 1.321 billion yuan in 2024 to 1.771 billion yuan in 2026, with year-on-year growth rates of 12.3% and 15.4% [2][8]

证券代码：300622 证券简称：博士眼镜 公告编号：2024-062 博士眼镜连锁股份有限公司 第五届董事会第五次会议决议公告 二、董事会会议审议情况 1、审议通过了《关于<2024 年半年度报告>全文及摘要的议案》 表决结果：9 票同意、0 票反对、0 票弃权 经审议，董事会认为公司《2024 年半年度报告》及摘要的编制和审议程序符 合法律、行政法规、中国证监会和深圳证券交易所的相关规定，报告内容真实、 准确、完整地反映了公司 2024 年上半年的实际经营情况，不存在任何虚假记载、 误导性陈述或者重大遗漏。 具体内容详见披露于巨潮资讯网（www.cninfo.com.cn）的相关公告。 2、审议通过了《关于 2024 年半年度利润分配预案的议案》 表决结果：9 票同意、0 票反对、0 票弃权 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 博士眼镜连锁股份有限公司（以下简称"公司"）第五届董事会第五次会议 通知于 2024 年 8 月 16 日以电子邮件的形式发出，会议于 2024 年 8 月 27 日上 午 10:30 在公司会议 ...

博士眼镜连锁股份有限公司章程 博士眼镜连锁股份有限公司章程 第一章 总则 第一条 为维护公司、股东和债权人的合法权益，规范公司的组织和行为，根 据《中华人民共和国公司法》（以下简称《公司法》）、《中华人民共和国证券法》 （以下简称《证券法》）和其他有关规定，制订本章程。 第二条 博士眼镜连锁股份有限公司系依照《公司法》和其他有关规定成立的 股份有限公司（以下简称"公司"）。 公司系由深圳市博士眼镜连锁有限公司按截止 2011 年 11 月 30 日经审计的原 账面净资产值折股整体变更设立的股份有限公司，在深圳市市场监督管理局注册登 记，取得营业执照，统一社会信用代码为 914403002793301026。 第三条 公司于 2017 年 2 月 10 日经中国证券监督管理委员会（以下简称中国 证监会）核准，首次向社会公众公开发行人民币普通股 2,145 万股，于 2017 年 3 月 15 日在深圳证券交易所创业板上市。 第四条 公司注册名称（中文）：博士眼镜连锁股份有限公司。 公司的英文名称：DOCTORGLASSES CHAIN CO.,LTD. 第五条 公司住所：深圳市罗湖区深南东路 5016 号京基一 ...

博士眼镜连锁股份有限公司 2024 年半年度非经营性资金占用及其他关联资金往来情况汇总表 1 / 3 2 / 3 | | 海口朗目贸易有限 | 本公司之 | 其他应 | | - | 94,377.09 | | - | 94,377.09 | 资金集中 | 非经营性往 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 公司 | 子公司 | 收款 | | | | | | | 管理 | 来 | | 其他关联方及其 | | | | | | | | | | | | | 附属企业 | | | | | | | | | | | | | 总计 | - | - | - | 61,939.05 | | 67,722,409.90 | 12,489,095.39 | | 55,295,253.56 | | - | 注：本表的关联方范围依照《深圳证券交易所创业板股票上市规则》确定。本表已于 2024 年 8 月 27 日获董事会批准。 法定代表人：ALEXANDER LIU 主管会计工作负责人：康海文 会计机构负责人：魏前喜 ...